Natera loses patent ruling in NeoGenomics litigation

Go back to Natera loses patent ruling in NeoGenomics litigation

Natera Provides Update on Patent Litigation with NeoGenomics

August 29, 2025 8:18 AM UTC

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.

The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents.

Importantly, these patents are distinct from U.S. Patent No. 11,519,035 (the 035 patent), and yesterdays decision has no impact on the... More